Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/22411, first published .
Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study

Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study

Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study

Journals

  1. Bennett A, Elliott L. Naloxone's role in the national opioid crisis—past struggles, current efforts, and future opportunities. Translational Research 2021;234:43 View
  2. Muroff J, Do D, Brinkerhoff C, Chassler D, Cortes M, Baum M, Guzman-Betancourt G, Reyes D, López L, Roberts M, De Jesus D, Stewart E, Martinez L. Nuestra Recuperación [Our Recovery]: using photovoice to understand the factors that influence recovery in Latinx populations. BMC Public Health 2023;23(1) View
  3. Sellen K, Goso N, Halleran L, Mulvale‐Fletcher A, Sarmiento F, Ligabue F, Handford C, Klaiman M, Milos G, Wright A, Charles M, Sniderman R, Hunt R, Parsons J, Leece P, Hopkins S, Shahin R, Jüni P, Morrison L, Campbell D, Strike C, Orkin A. Design details for overdose education and take‐home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community. Health Expectations 2022;25(5):2440 View
  4. Nguyen T, Applewhite D, Cheung F, Jacob S, Mitchell E. Implementation of a multidisciplinary inpatient opioid overdose education and naloxone distribution program at a large academic medical center. American Journal of Health-System Pharmacy 2022;79(24):2253 View
  5. Cheetham A, Picco L, Barnett A, Lubman D, Nielsen S. The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. Substance Abuse and Rehabilitation 2022;Volume 13:1 View
  6. Aronson I, Bennett A, Ardouin-Guerrier M, Rivera-Castellar G, Gibson B, Santoscoy S, Vargas-Estrella B. How Vaccine Ambivalence Can Lead People Who Inject Drugs to Decline COVID-19 Vaccination and Ways This Can Be Addressed: Qualitative Study. JMIR Formative Research 2022;6(3):e35066 View
  7. Bodnar R. Endogenous opiates and behavior: 2020. Peptides 2022;151:170752 View
  8. Strickland J, Marks K, Smith K, Ellis J, Hobelmann J, Huhn A. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose. International Journal of Drug Policy 2022;106:103751 View
  9. Wagner K, Marks C, Felsher M, Latkin C, Pearson J, Falade-Nwulia O. Individual and social network correlates of responding to multiple overdoses among a cohort of people who use drugs. Drug and Alcohol Dependence Reports 2022;5:100107 View
  10. Grant S, Smart R. Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process. Harm Reduction Journal 2022;19(1) View
  11. Hill L, Zagorski C, Loera L. Increasingly powerful opioid antagonists are not necessary. International Journal of Drug Policy 2022;99:103457 View
  12. Kozak Z, Ciccarone D, Thrul J, Cole T, Pappas A, Greenblatt A, Welsh C, Yoon M, Gann D, Artigiani E, Wish E, Belcher A. Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment. Harm Reduction Journal 2023;20(1) View
  13. Adeosun S. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?. Journal of Pharmacy Practice 2023;36(4):941 View
  14. Abdelal R, Banerjee A, Carlberg-Racich S, Cebollero C, Darwaza N, Kim C, Ito D, Epstein J. Real-World Study of Multiple Naloxone Administrations for Opioid Overdose Reversal among Emergency Medical Service Providers. Substance Abuse 2022;43(1):1075 View
  15. Bennett A, Guarino H, Britton P, O’Brien-Mazza D, Cook S, Taveras F, Cortez J, Elliott L. U.S. Military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts. Annals of Medicine 2022;54(1):1826 View
  16. Aronson I, Bennett A, Ardouin-Guerrier M, Rivera-Castellar G, Gibson B, Vargas-Estrella B. Using the participatory education and research into lived experience (PEARLE) methodology to localize content and target specific populations. Frontiers in Digital Health 2022;4 View
  17. Strang J. Take-Home Naloxone and the Prevention of Deaths from Heroin Overdose: Pursuing Strong Science, Fuller Understanding, Greater Impact. European Addiction Research 2022;28(3):161 View
  18. Walters S, Felsher M, Frank D, Jaiswal J, Townsend T, Muncan B, Bennett A, Friedman S, Jenkins W, Pho M, Fletcher S, Ompad D. I Don’t Believe a Person Has to Die When Trying to Get High: Overdose Prevention and Response Strategies in Rural Illinois. International Journal of Environmental Research and Public Health 2023;20(2):1648 View
  19. Khan M, Hoff L, Elliott L, Scheidell J, Pamplin J, Townsend T, Irvine N, Bennett A. Racial/ethnic disparities in opioid overdose prevention: comparison of the naloxone care cascade in White, Latinx, and Black people who use opioids in New York City. Harm Reduction Journal 2023;20(1) View
  20. Pakieser J, Peters S, Tilley L, Costantino R, Scott-Richardson M, Highland K. Naloxone prescribing practices in the Military Health System before and after policy implementation. PAIN Reports 2022;7(2):e993 View
  21. Voronkov M, Nikonov G, Ataiants J, Isakulyan L, Stefanut C, Cernea M, Abernethy J. Modifying naloxone to reverse fentanyl-induced overdose. International Journal of Pharmaceutics 2022;611:121326 View
  22. Spector A, Galletly C, Christenson E, Montaque H, Dickson-Gomez J. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin. BMC Public Health 2022;22(1) View
  23. Rothbauer K, Genisot A, Frey T, Johnson D. Integration of Pharmacy Student Interns into a Naloxone Telephone Outreach Service. Journal of Pain & Palliative Care Pharmacotherapy 2022;36(4):208 View
  24. McMahan V, Arenander J, Matheson T, Lambert A, Brennan S, Green T, Walley A, Coffin P. “There’s No Heroin Around Anymore. It’s All Fentanyl.” Adaptation of an Opioid Overdose Prevention Counseling Approach to Address Fentanyl Overdose: Formative Study. JMIR Formative Research 2022;6(9):e37483 View
  25. Zhang I, Flum D, Agrawal N, Liao J. Effects of opioid addiction risk information on Americans’ agreement with postoperative opioid minimization and perceptions of quality. Healthcare 2022;10(2):100629 View
  26. Parkes T, Foster R, McAuley A, Steven D, Matheson C, Baldacchino A. Chronic pain, prescribed opioids and overdose risk: a qualitative exploration of the views of affected individuals and family members. Drugs: Education, Prevention and Policy 2023;30(3):229 View
  27. Schneider K, Rouhani S, Weicker N, Morris M, Sherman S. Businesses in high drug use areas as potential sources of naloxone during overdose emergencies. Drug and Alcohol Dependence 2022;233:109357 View
  28. Fernandez P, Azucar D, Zambole K. A Dose of Truth: A Qualitative Assessment of Reactions to Messages about Fentanyl for People Who Use Drugs. Substance Use & Misuse 2023;58(4):520 View
  29. Spring C, Croxford S, Ward Z, Ayres R, Lord C, Desai M, Emanuel E, Vickerman P, Artenie A. Perceived availability and carriage of take-home naloxone and factors associated with carriage among people who inject drugs in England, Wales and Northern Ireland. International Journal of Drug Policy 2022;102:103615 View
  30. Bennett A, Scheidell J, Bowles J, Khan M, Roth A, Hoff L, Marini C, Elliott L. Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City. Harm Reduction Journal 2022;19(1) View
  31. Resko S, Pasman E, Hicks D, Lee G, Ellis J, O’Shay S, Brown S, Agius E. Naloxone Knowledge and Attitudes Towards Overdose Response Among Family Members of People who Misuse Opioids. Journal of Community Health 2024;49(1):70 View
  32. Kesich Z, Ibragimov U, Komro K, Lane K, Livingston M, Young A, Cooper H. “I’m not going to lay back and watch somebody die”: a qualitative study of how people who use drugs’ naloxone experiences are shaped by rural risk environment and overdose education/naloxone distribution intervention. Harm Reduction Journal 2023;20(1) View
  33. Chavanne D, Ahluwalia J, Goodyear K. The effects of race and class on community-level stigmatization of opioid use and policy preferences. International Journal of Drug Policy 2023;120:104147 View
  34. Marks K, Oyler D, Strickland J, Jaggers J, Roberts M, Miracle D, Barnes C, Lei F, Smith A, Mackin E, Martin M, Freeman P. Bystander preference for naloxone products: a field experiment. Harm Reduction Journal 2023;20(1) View
  35. Ezell J, Ajayi B, Parikh T, Miller K, Rains A, Scales D. Drug Use and Artificial Intelligence: Weighing Concerns and Possibilities for Prevention. American Journal of Preventive Medicine 2024;66(3):568 View
  36. Infante A, Elmes A, Gimbar R, Messmer S, Neeb C, Jarrett J. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement. International Journal of Drug Policy 2024;124:104323 View
  37. Lyzwinski L, Elgendi M, Menon C. Users' Acceptability and Perceived Efficacy of mHealth for Opioid Use Disorder: Scoping Review. JMIR mHealth and uHealth 2024;12:e49751 View
  38. Garcia V, McCann L, Lauber E, Vaccaro C, Swauger M, Heckert D. Opioid Overdoses and Take-Home Naloxone Interventions: Ethnographic Evidence for Individual-Level Barriers to Treatment of Opioid Use Disorders in Rural Appalachia. Substance Use & Misuse 2024;59(9):1313 View